Instituto de Investigación Hospital Universitario La Paz
idipaz.esLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
104
Active
11
Phase 3
5
Total enrollment
16,615
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Isoflurane | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | — | 1 | |
| Botulinum Toxin A | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Colchicine 0.5 mg | — | — | — | — | — | 1 | |
| NK cells stimulated ex vivo with IL-15 | — | — | — | — | — | 1 | |
| Alloreactive NK cells | — | — | — | — | — | 1 | |
| Intravenous dobutamine 5 mcg/kg/min | — | — | — | — | — | 1 | |
| Intravenous dobutamine 7.5 mcg/kg/min | — | — | — | — | — | 1 | |
| Intravenous dobutamine 10 mcg/kg/min | — | — | — | — | — | 1 | |
| Intravenous dobutamine 12.5 mcg/kg/min | — | — | — | — | — | 1 | |
| Intravenous dobutamine 15 mcg/kg/min | — | — | — | — | — | 1 | |
| Autologous CD19/CD22 CAR T cells | — | — | — | — | — | 1 | |
| Allogeneic CART-NKG2D cells | — | — | — | — | — | 1 | |
| Whole genome sequencing | — | — | — | — | — | 1 | |
| Polygenic Risk Score Calculation | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-06-30
- 2026-10-01
- 2027-03
- 2028-01
- 2028-12
- 2029-06
- 2030-06-01
Top conditions
- Overweight6
- Cancer5
- Malnutrition5
- Breast Cancer4
- Nutrition Related Cancer4
- Ischemic Stroke3
- Healthy3
- Obesity and Overweight2
Frequently asked questions about Instituto de Investigación Hospital Universitario La Paz
- How many clinical trials does Instituto de Investigación Hospital Universitario La Paz have on ClinicalTrials.gov?
- Instituto de Investigación Hospital Universitario La Paz is listed as the lead sponsor on 104 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Instituto de Investigación Hospital Universitario La Paz's trials are in Phase 3?
- 5 of Instituto de Investigación Hospital Universitario La Paz's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Instituto de Investigación Hospital Universitario La Paz focus on?
- Instituto de Investigación Hospital Universitario La Paz's most-studied conditions on ClinicalTrials.gov are Overweight, Cancer, Malnutrition, Breast Cancer, Nutrition Related Cancer.
- When are Instituto de Investigación Hospital Universitario La Paz's next clinical trial readouts?
- Instituto de Investigación Hospital Universitario La Paz has 8 upcoming primary-completion readouts tracked here; the soonest is “A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.”, expected around 2026-06.